New Video Works As A Tool To Combat The Opioid Epidemic

SALT LAKE CITY, UTAH, USA, March 31, 2017 /EINPresswire.com/ — Intermountain Healthcare has been tackling the opioid epidemic locally and nationally, including a new video titled "Opioids for Chronic Pain Management" to help educate patients, families, and the community about the risks and precautions of opioid therapy for chronic pain.

The six-minute video provides important information about the risks and benefits of opioid medications. It highlights potential opioid side-effects and explains the benefits of Naloxone, a life-saving medication that counters opioid overdose. It also shares the true story of an amputee patient who worked with his physician to successfully manage his chronic pain without opioids after years of opioid therapy.

The video talks common side effects of opioids, alternative pain relieving methods including meditation and physical therapy, steps to avoid an overdose, and questions to ask your doctor on if you need the opioids to begin with.

The video is part of Intermountain’s effort to reduce the growing problem of opioid-related addiction and resulting deaths in the United States — and in Utah. The health system’s approach works on reducing the number of opioid prescriptions be written as well.

Intermountain also partners with community leaders, public safety entities, and health organizations on several opioid community programs. One example is the program Use Only As Directed. The initiative educates the public on safe storage and disposal of medications, including medications drop boxes. Intermountain pharmacies have drop boxes and have seen 11,000 tons pounds of medications turned in by the public in under two years.

The “Opioids for Chronic Pain Management” video can be found on Intermountain’s YouTube site.

Intermountain Healthcare is a not-for-profit system of 22 hospitals, 180 clinics, a Medical Group with about 1,500 employed physicians and advanced practitioners, a health plans group called SelectHealth, and other medical services. Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit www.intermountainhealthcare.org.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

Global HIV Vaccines Market Research Report 2017 Analysis and Forecast to 2027



HIV Vaccines Market

WiseGuyReports.com adds “HIV Vaccines Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2027”reports to its database

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — HIV Vaccines Market:

Executive Summary

Vaccines empower the human immune system to protect against infection or disease. Vaccines against HIV are being developed, and tested in phases of clinical trials. At present, none of the HIV vaccines are commercially available.

More than 30 HIV candidate vaccines have been tried in roughly 60 Phase I/II trials, involving more than 10,000 healthy volunteers. A large portion of these trials have been conducted in the United States & Europe, and a few in developing countries such as Brazil, Peru, China, and Thailand. The outcomes have affirmed the safety of the vaccines, and have given important scientific information to create fresher eras of candidate vaccines with better capacity to induce anti-HIV specific immune responses.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/860844-global-hiv-vaccines-market-development-and-forecast-to-2027

This research report provides in-depth information about the various market segments. It shall also provide qualitative information about the current and upcoming trends in HIV vaccines market, globally.
The market is majorly divided on the basis of phases of clinical trials and regions. Globally, North America commands the largest market share of around 44% of the global market. This large share is majorly attributed to high adoption of various HIV vaccine trials coupled with the technological advancement in the region. North America is one of the important partners for HIV prevention & research for the development of HIV vaccine, as well as for reduction and prevention of HIV. It has been revealed that more than $600 million a year is invested into HIV vaccine R&D, with the major share coming from the US National Institutes of Health. United States was the first country to carry out the first Phase I trial of an HIV candidate vaccine in 1987. Since then, more than 30 distinctive candidate vaccines have been developed by many organizations, utilizing various technologies mostly in the United States.

Growing number of market players, increasing awareness about HIV prevention among various nations, rising prevalence of HIV, and rising funds for HIV vaccines research, are some of the key factors propelling the growth of HIV vaccines market. However, hindrance during HIV vaccine approval process is limiting the market growth to a great extent.

Some of the key players of the market are GlaxoSmithKline plc (U.K.), SANOFI (France), Argos Therapeutics, Inc. (U.S.), Bionor Pharma ASA (Norway), Janssen Global Services, LLC (U.S.), GENECURE LLC (U.S.), GeoVax (U.S.), GENVEC, INC. (U.S.), PaxVax Corporation (U.S.), and Inovio Pharmaceuticals, Inc. (U.S.).

STUDY OBJECTIVES OF HIV VACCINES MARKET DEVELOPMENT AND FORECAST TO 2027
• To provide insights about factors, influencing and affecting the market growth
• To provide present and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries
• To provide present as well as forecast revenue of the market segments based on products, and sub-segments for global HIV vaccines market
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic and ethical factors that influences the global HIV vaccines market

Target Audience
• Pharmaceutical companies
• Research Laboratories
• Hospitals & Clinics
• Service Suppliers
• Potential Investors
• Key executive (CEO and COO) and strategy growth manager

Access Report @ https://www.wiseguyreports.com/reports/860844-global-hiv-vaccines-market-development-and-forecast-to-2027

Key Findings
• The global HIV vaccines market is expected to grow at a CAGR of 5.0% between 2017 and 2027, driven by growth from both developed and emerging markets
• North America contributed more than 44% of the total market size in 2017. Emerging markets such as China and India are expected to generate significant demand for HIV vaccines during the period, 2017-2027

As per the MRFR analysis, the global HIV vaccines market is expected to reach $2.7 billion by 2027. The market in Europe is estimated to be around $ 437 million in 2017 and is anticipated to reach $ 757 million by 2027. Asia-Pacific is expected to grow at a moderate pace during the forecast period.

The reports also cover country level analysis:
• Americas
o North America
§ US
§ Canada
o South America
• Europe
o Western Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Western Europe
o Easter Europe
• Asia-Pacific
o China
o Japan
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=860844

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Seborrhea Therapeutic and Drug Pipeline Review H1


.

.

Seborrhea Treatment Pipeline Review H1 2017

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — Seborrhea – Pipeline Review, H1 2017

Summary
Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1095886-seborrhea-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Seborrhea – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 2 respectively.

Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Seborrhea – Overview
Seborrhea – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Seborrhea – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Seborrhea – Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Amorepacific Corp
Biomar Microbial Technologies
EpiPharm AG
Phosphagenics Ltd
Vyome Biosciences Pvt Ltd
Seborrhea – Drug Profiles
artemether – Drug Profile
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1095886-seborrhea-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Learning Management System market expected to reach at USD ~17 billion by 2022 with stable CAGR of 22%

Learning Management System Market, by Application, by Deployment, by Service (Administration, Performance Management, Content Management) – Forecast 2022

Major key Players include Edmodo,Blackboard, Inc.,IBM corporation,SAP SE,Xerox corporation,Oracle Corporation,McGraw-Hill Education,D2L Corporation”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, March 30, 2017 /EINPresswire.com/ — Market Highlights
The global Learning Management System market has been evaluated as growing market and expected that the market will touch high growth figures in upcoming years.
Absorb LMS, Moodle LMS, D2L bright space LMS, Edmodo LMS, and Canvas LMS are some of the popular learning management software in the market. Major industries such as IBM Corporation, Xerox Corporation, Oracle Corporation, and Edmodo among other prominent players are serving the demand of learning management software by industries such as corporate and academics among others.

Market research future published a half-cooked research report on Learning Management System market. The global market for Learning Management System market is expected to grow over the CAGR of around ~22% during the period 2016 to 2022 and expected to grow at market size of USD ~17 billion in 2022.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1858

Key Players for learning Management System Market:
• Edmodo (California)
• Blackboard, Inc. (U.S.)
• IBM corporation (U.S.)
• SAP SE (Germany)
• Xerox corporation (U.S.)
• Oracle Corporation (U.S.)
• McGraw-Hill Education (U.S.)
• Cornerstone On demand, Inc. (U.S.)
• D2L Corporation (Canada),
• Saba Software, Inc. (U.S.) among others.

“Growing need for Learning Management System for training & development especially in academics and corporate sector is the key trend for this market. Growing cloud computing technology is developing opportunity for software developers to build efficient learning management software to serve the growing demand and therefore, America and Asia-pacific countries are taking many initiatives to build strong market of Learning Management System in the region “

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Learning Management System Market Research Report- Global Forecast to 2022

Target Audience:
• Hardware and software service providers
• Education sector
• System administrators
• Network service providers
• Corporate training
• Government

Table of Content
1. Report prologue
2. Introduction
2.1 Definition
2.2 Scope of the study
2.2.1 Research objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market structure
3. Research Methodology
3.1 Research process
3.2 Primary research
3.3 Secondary research
3.4 Market size estimation
3.5 Forecast model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Market factor analysis
Continue……

List of Tables
Table 1 Global Learning Management System Market (Usd Billion)
Table 2 Global Learning Management System Market, By Services
Table 3 Global Content Management Market, By Region
Table 4 Global Performance Management Market, By Region
Table 5 Global Administration Market, By Region
Table 6 Global Communication & Collaboration Market, By Region
Continue…….

List of Figures
Figure 1 Research Process
Figure 2 Drivers Of Global Learning Management System Market
Figure 3 Global Learning Management System Market: By Services (%)
Figure 4 Global Learning Management System Market: By Application
Figure 5 Global Learning Management System Market Share By Region
Figure 6 North America Learning Management System Market, By Services
Continue….

Browse full report with detail TOC @ https://www.marketresearchfuture.com/reports/learning-management-system-market

The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Related Report
Global Mobile Application Development Market, by Platform (IOS, Android), by Application (E-commerce, Banking, Entertainment (Gaming, Media), Education, Government Agencies, Airline Industry) – Forecast 2022.Know more about this report @ https://www.marketresearchfuture.com/reports/mobile-app-development-market

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

Atopic Dermatitis Therapeutic and Drug Pipeline Review H1


.

.

Atopic Dermatitis Therapeutic Pipeline Market Review, H1 2017

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — Atopic Dermatitis – Pipeline Review, H1 2017

Summary
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1095885-atopic-dermatitis-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 40, 21, 1, 44, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 2 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Atopic Dermatitis – Overview 12
Atopic Dermatitis – Therapeutics Development 13
Pipeline Overview 13
Pipeline by Companies 14
Pipeline by Universities/Institutes 20
Products under Development by Companies 21
Products under Development by Universities/Institutes 28
Atopic Dermatitis – Therapeutics Assessment 29
Assessment by Target 29
Assessment by Mechanism of Action 33
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Atopic Dermatitis – Companies Involved in Therapeutics Development 41
AbbVie Inc 41
Accolade Pharmaceuticals LLC 41
Albireo Pharma Inc 42
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1095885-atopic-dermatitis-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

DevOps Platform Market 2017 Global Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2022

DevOps Platform Global Market Segmentation, Major Players Analysis and Forecast to 2022

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — This report studies the global DevOps Platform market, analyzes and researches the DevOps Platform development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Ansible
Chef
Puppet Labs
Jenkins
TeamCity
Atlassian
SaltStack
Vagrant
Splunk
ServiceNow
CA Technologies
IBM
Rackspace
Red Hat
CFEngine
Cisco
Clarive
CollabNet
DBmaestro
Dell
Docker
HP
Inedo
Infosys
Microsoft
VersionOne
VMware
Request a sample report @ https://www.wiseguyreports.com/sample-request/1137633-global-devops-platform-market-size-status-and-forecast-2022
Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia
Market segment by Type, DevOps Platform can be split into
Developer-Driven Devops
Operations-Driven Devops
Platform 2.5 Type Of Environment
Market segment by Application, DevOps Platform can be split into
IT Industry
Banking, Financial Services and Insurance (BFSI) Sector
Telecom Sector
Retail Sector
Other end-users
Complete report details @ https://www.wiseguyreports.com/reports/1137633-global-devops-platform-market-size-status-and-forecast-2022
Key points in table of content
1 Industry Overview of DevOps Platform
1.1 DevOps Platform Market Overview
1.1.1 DevOps Platform Product Scope
1.1.2 Market Status and Outlook
1.2 Global DevOps Platform Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 DevOps Platform Market by Type
1.3.1 Developer-Driven Devops
1.3.2 Operations-Driven Devops
1.3.3 Platform 2.5 Type Of Environment
1.4 DevOps Platform Market by End Users/Application
1.4.1 IT Industry
1.4.2 Banking, Financial Services and Insurance (BFSI) Sector
1.4.3 Telecom Sector
1.4.4 Retail Sector
1.4.5 Other end-users
2 Global DevOps Platform Competition Analysis by Players
2.1 DevOps Platform Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Ansible
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 DevOps Platform Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Chef
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 DevOps Platform Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Puppet Labs
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 DevOps Platform Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Jenkins
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 DevOps Platform Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 TeamCity
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 DevOps Platform Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Atlassian
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 DevOps Platform Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 SaltStack
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 DevOps Platform Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Vagrant
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 DevOps Platform Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 Splunk
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 DevOps Platform Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 ServiceNow
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 DevOps Platform Revenue (Value) (2012-2017)
3.10.5 Recent Developments
3.11 CA Technologies
3.12 IBM
3.13 Rackspace
3.14 Red Hat
3.15 CFEngine
3.16 Cisco
3.17 Clarive
3.18 CollabNet
3.19 DBmaestro
3.20 Dell
3.21 Docker
3.22 HP
3.23 Inedo
3.24 Infosys
3.25 Microsoft
3.26 VersionOne
3.27 VMware
4 Global DevOps Platform Market Size by Type and Application (2012-2017)
4.1 Global DevOps Platform Market Size by Type (2012-2017)
4.2 Global DevOps Platform Market Size by Application (2012-2017)
4.3 Potential Application of DevOps Platform in Future
4.4 Top Consumer/End Users of DevOps Platform
5 United States DevOps Platform Development Status and Outlook
5.1 United States DevOps Platform Market Size (2012-2017)
5.2 United States DevOps Platform Market Size and Market Share by Players (2016 and 2017)
6 EU DevOps Platform Development Status and Outlook
6.1 EU DevOps Platform Market Size (2012-2017)
6.2 EU DevOps Platform Market Size and Market Share by Players (2016 and 2017)
7 Japan DevOps Platform Development Status and Outlook
7.1 Japan DevOps Platform Market Size (2012-2017)
7.2 Japan DevOps Platform Market Size and Market Share by Players (2016 and 2017)
8 China DevOps Platform Development Status and Outlook
8.1 China DevOps Platform Market Size (2012-2017)
8.2 China DevOps Platform Market Size and Market Share by Players (2016 and 2017)
9 India DevOps Platform Development Status and Outlook
9.1 India DevOps Platform Market Size (2012-2017)
9.2 India DevOps Platform Market Size and Market Share by Players (2016 and 2017)
10 Southeast Asia DevOps Platform Development Status and Outlook
10.1 Southeast Asia DevOps Platform Market Size (2012-2017)
10.2 Southeast Asia DevOps Platform Market Size and Market Share by Players (2016 and 2017)
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1137633
Contact US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Scar Therapeutic and Drug Pipeline Review H1


.

.

Scar Treatment Pipeline Review H1 2017

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — Scar – Pipeline Review, H1 2017

Summary
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1095884-scar-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Scar – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Scar – Overview
Scar – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Scar – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Scar – Companies Involved in Therapeutics Development
3M Drug Delivery Systems
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1095884-scar-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Pruritus Therapeutic and Drug Pipeline Review H1


.

.

Pruritus – Pipeline Review, H1 2017

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — Pruritus – Pipeline Review, H1 2017

Summary
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1095883-pruritus-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Pruritus – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 12, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Pruritus – Overview
Pruritus – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pruritus – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pruritus – Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Alveonix AG
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1095883-pruritus-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Burns Therapeutic and Drug Pipeline Review H1


.

.

Burns Therapeutic Pipeline Market Review, H1 2017

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — Burns – Pipeline Review, H1 2017

Summary
A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1095882-burns-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Burns – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 2, 11, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Burns – Overview
Burns – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burns – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burns – Companies Involved in Therapeutics Development
AlgiPharma AS
Alliance Pharma Plc
Amarantus Bioscience Holdings Inc
American Gene Technologies International Inc
Biogenomics Ltd
CytoTools AG
Destiny Pharma Ltd
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1095882-burns-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Spinal Muscular Atrophy Therapeutic and Drug Pipeline Review H1


.

.

Global Spinal Muscular Atrophy Drugs and Companies Pipeline Review H1 2017

PUNE, INDIA, March 30, 2017 /EINPresswire.com/ — Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2017

Summary
Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1095881-spinal-muscular-atrophy-sma-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 2, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Spinal Muscular Atrophy (SMA) – Overview
Spinal Muscular Atrophy (SMA) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinal Muscular Atrophy (SMA) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinal Muscular Atrophy (SMA) – Companies Involved in Therapeutics Development
AveXis Inc
Cytokinetics Inc
F. Hoffmann-La Roche Ltd
Genethon SA
Genzyme Corp
Ionis Pharmaceuticals Inc
Kowa Company Ltd
Neurotune AG
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1095881-spinal-muscular-atrophy-sma-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire